CASE REPORT

Acrual hemorrhagic Darier disease: A case report of a rare presentation and literature review

Emily Hong, BS,a Ronghua Hu, MD,b,c,d Alba Posligua, MD,e Keith Choate, MD, PhD,b,c,d and John R. Durkin, MD, MBAe

Key words: Acrual hemorrhagic lesions; ATP2A2; Darier disease.

INTRODUCTION

Acrual hemorrhagic lesions are an extremely rare feature of Darier disease (DD) that may present in the first 2 decades of life. Clinically, this manifestation of DD is characterized by irregular, jagged-shaped, minute hemorrhagic vesicles on the hands and feet. Histopathology shows irregular acanthosis and suprabasal acantholysis with dyskeratosis (corps, grains, and ronds), which are the characteristics of non-hemorrhagic DD lesions, along with extensive accumulation of intact erythrocytes in suprabasal clefts, which is unique to this unusual presentation. Although a mutation in exon 15 of the sarcoplasmic/endoplasmic reticulum calcium-ATPase 2 (ATP2A2) gene, which encodes a sarcoplasmic/endoplasmic reticulum calcium-ATPase pump (SERCA2), is found in 71% of genetically tested patients with DD and acral hemorrhagic lesions, few cases have reported conflicting genetic results, and no specific genotype-phenotype correlation has been established (Table I).1-15 This feature has also been observed in patients with DD after they receive systemic retinoids. Herein, we report 2 cases of familial DD with acral hemorrhagic features and review other cases reported in the literature.

CASE REPORT

A 41-year-old man presented with multiple, focal, black hemorrhagic vesicles with jagged borders on the dorsal and palmar aspects of both hands and feet. In addition, subtle red and white streaks as well as distal nicking were noted in his nails. The patient reported having this condition for several years and had used triamcinolone ointment 0.1%, with mild improvement. A punch biopsy of the left palm showed a hemorrhage in the cornified layer with suprabasal acantholysis; therefore, the patient was diagnosed with acral hemorrhagic DD. Notably, the patient’s mother had a similar rash affecting the hands and feet (Fig 1). The patient was employed at a fast-food restaurant and experienced repeat trauma to his hands, which exacerbated the condition. Genetic testing revealed a p.N676S mutation in the ATP2A2 gene, a mutation that has not been previously found in patients with acral hemorrhagic DD.

Acitretin at 25 mg daily and betamethasone dipropionate ointment 0.05% were initiated for the patient. Because of mild improvement after 2 months of treatment, the acitretin dose was increased to 50 mg/d; however, an eruption resembling classic DD soon developed on his face and chest, which caused him to discontinue acitretin.

Abbreviations used:
DD: Darier disease
SERCA2: sarcoplasmic reticulum calcium-ATPase pump

In addition, subtle red and white streaks as well as distal nicking were noted in his nails. The patient reported having this condition for several years and had used triamcinolone ointment 0.1%, with mild improvement. A punch biopsy of the left palm showed a hemorrhage in the cornified layer with suprabasal acantholysis; therefore, the patient was diagnosed with acral hemorrhagic DD. Notably, the patient’s mother had a similar rash affecting the hands and feet (Fig 1). The patient was employed at a fast-food restaurant and experienced repeat trauma to his hands, which exacerbated the condition. Genetic testing revealed a p.N676S mutation in the ATP2A2 gene, a mutation that has not been previously found in patients with acral hemorrhagic DD.

Acitretin at 25 mg daily and betamethasone dipropionate ointment 0.05% were initiated for the patient. Because of mild improvement after 2 months of treatment, the acitretin dose was increased to 50 mg/d; however, an eruption resembling classic DD soon developed on his face and chest, which caused him to discontinue acitretin.

From University of New Mexico School of Medicine, Albuquerque, New Mexicoa Department of Dermatology, Yale University School of Medicine, New Haven, Connecticutb; Department of Genetics, Yale University School of Medicine, New Haven, Connecticutc; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut; and Department of Dermatology, University of New Mexico School of Medicine, Albuquerque, New Mexico. Funding source: Supported by Yale University School of Medicine (R01AR068392).

IRB approval status: Not applicable.

Correspondence to: John R. Durkin, MD, MBA, Department of Dermatology, University of New Mexico School of Medicine, 1021 Medical Arts Ave NE, Albuquerque, NM 87102. E-mail: jdurkin@salud.unm.edu.

JAAD Case Reports 2023;31:93-6.
2352-5126 © 2022 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.jdcr.2022.05.030
Table I. Literature review of case reports and case series

| Case no. | Age, y | Sex, race | Location | Initial presentation | Triggers | Treatments | ATP2A2 mutation | Author, year published |
|----------|--------|-----------|----------|----------------------|----------|------------|-----------------|------------------------|
| 1*       | 35, 14 | Female, White | USA | Both | Trauma | N/A | N/A | Jones et al, 1 1964 |
| 2        | 56     | Male, White | USA | Both | Trauma | N/A | N/A | Jones et al, 1 1964 |
| 3        | 58     | Female, White | USA | Both | Trauma | N/A | N/A | Jones et al, 1 1964 |
| 4        | 43     | Female | UK | Hemorrhagic | Trauma and UV | N/A | N/A | Coulson and Misch, 2 1989 |
| 5        | 47     | Female, White | UK | Classic | Retinoid | 25 mg/d of etretinate | N/A | Gebauer et al, 4 1993 |
| 6*       | N/A    | N/A | USA | N/A | Trauma | N/A | N/A | Foresman et al, 4 1993 |
| 7*       | 48, 32, 12 | Female | Italy | Classic | N/A | N/A | p.N767S | Regazzini et al, 5 1996 |
| 8        | 76     | Female | Germany | Classic | Trauma and UV | N/A | N/A | Jörig et al, 6 1997 |
| 9*       | N/A    | N/A | Scotland | N/A | N/A | N/A | p.N767S | Ruiz-Perez et al, 7 1999 |
| 10*      | N/A    | N/A | Italy | N/A | N/A | N/A | p.N767S | Ruiz-Perez et al, 7 1999 |
| 11*      | N/A    | N/A | Sweden | N/A | N/A | N/A | C268F | Ruiz-Perez et al, 7 1999 |
| 12       | 28     | Male | Croatia | Classic | UV | 40 mg/d acitretin, topical antiseptics, and keratolytics | No mutation in exon 15 | Pecina-Slaus et al, 8 2003 |
| 13*      | 34     | N/A | Japan | Both | Friction | N/A | p.N767S | Hamada et al, 9 2007 |
| 14       | 48     | Male | Spain | Classic | Summer trauma | 10 mg/d of acitretin, antihistamines, 5-fluorouracil cream, and topical tazarotene | No mutation in ATP2A2 | Sánchez-Salas et al, 10 2011 |
| 15       | 84     | Female | Italy | Classic | Retinoid | Acitretin | No mutation in ATP2A2 | Zavattaro et al, 11 2014 |
| 16       | 38     | Female | USA | Hemorrhagic | N/A | N/A | N/A | Boes et al, 12 2016 |
| 17       | 65     | Female | Canada | Hemorrhagic | N/A | Topical tretinoin | N/A | Vender and Vender, 13 2016 |
| 18*      | 50, 28 | N/A | Spain | Both | Trauma | 25 mg of acitretin, topical tretinoin, and 20 mg/d of isotretinoin | N/A | Flores-Terry et al, 14 2017 |
| 19       | 60     | Female | Spain | Classic | Trauma | N/A | N/A | Flores-Terry et al, 14 2017 |
| 20       | 40     | Male, Maltese | Australia | Classic | Retinoid trauma | 10 mg of acitretin 3 times/wk | N/A | Nguyen et al, 15 2018 |
| 21*      | 41     | Male, Hispanic | USA | Hemorrhagic | Trauma | 25 mg/d of acitretin, betamethasone dipropionate ointment 0.05% | p.N676S | Our case |

ATP2A2, Sarcoplasmic/endoplasmic reticulum calcium-ATPase 2; N/A, not available; UK, United Kingdom; USA, United States of America.
*Case reported in a kindred.
DISCUSSION

Twenty cases of DD with acral hemorrhagic features, with 79% in female patients, have been reported in the literature (Table I). Eight of these cases described this phenotype to be transmitted within a kindred. Furthermore, only 3 of these cases reported purely hemorrhagic DD initially, similar to our patient and his mother, although these patterns of presentation depend on multiple factors, including the time of evaluation. In most cases, classic DD papules developed first in the individuals, and acral hemorrhagic lesions developed only later on in life or after treatment with a systemic retinoid. Oral acitretin and isotretinoin, topical 5-fluorouracil, and topical retinoids have been used to treat hemorrhagic lesions, with variable results. Acitretin, the most common treatment, resulted in mild improvement in some cases. Notably, there have also been several cases of retinoid-induced acral hemorrhagic blisters in patients with DD successfully treated with etretinate and acitretin. In our patient, acitretin improved the hemorrhagic lesions but exacerbated the classic DD lesions on nonacral sites.

In cases of the acral hemorrhagic presentation of DD, certain mutations in the ATP2A2 gene may disrupt SERCA2 function in the vascular endothelium in addition to in keratinocytes or may produce a mutant SERCA2 protein that has a secondary effect in blood vessels. The hemorrhagic phenotype may only present after local trauma, retinoid use, or UV radiation in the setting of reduced epidermal cohesion because these events impair calcium homeostasis beyond the compensatory ability of the normal allele and other mechanisms. Given the established relationship between retinoids and photosensitivity, it is likely that retinoid use and UV radiation are interrelated predisposing factors for acral hemorrhagic lesions. It has been suggested that retinoic acid
increases epidermal fragility and activates vascular endothelial growth factor gene transcription, modifying the permeability of endothelial cells and inducing the congregation of red blood cells into intraepidermal lacunae emptied via acantholysis and abnormal keratinization in patients with classic DD, leading to hemorrhagic blistering. ^3,11^ Hypoxia and UV radiation have also been shown to upregulate vascular endothelial growth factor in dermal fibroblasts and epidermal keratinocytes. ^16,17^ In 1 case, only acral hemorrhagic bullae developed in a patient who had taken 10 mg of acitretin daily 3 times weekly for 15 years after they endured trauma to the hands, suggesting that a combination of these factors is necessary to induce hemorrhagic blisters. Hemorrhagic lesions may not develop in patients who avoid these triggers, possibly explaining why some patients with ATP2A2 mutations do not show the phenotype. Further investigation of the effects of oral retinoid treatment and other options, in addition to that of the genetic basis of acral hemorrhagic DD, is needed.

**Conflicts of interest**

Dr Choate has been an investigator for Alderya, Anaptysys, Galderma, Mayne, and Regeneron and a consultant with honorarium for AbbVie, Eli Lilly, Janssen, Anaptsys, Galderma, Mayne, and Regeneron and a consultant with honorarium for AbbVie, Eli Lilly, Janssen, Anaptsys, Galderma, Mayne, and Regeneron and a consultant with honorarium for AbbVie, Eli Lilly, Janssen, Anaptsys, Galderma, Mayne, and Regeneron and a consultant with honorarium for AbbVie, Eli Lilly, Janssen, Anaptsys, Galderma, Mayne, and Regeneron and a consultant with honorarium for AbbVie, Eli Lilly, Janssen, Anaptsys, Galderma, Mayne, and Regeneron and a consultant with honorarium for AbbVie, Eli Lilly, Janssen, Anaptsys, Galderma, Mayne, and Regeneron and a consultant with honorarium for AbbVie, Eli Lilly, Janssen, Anaptsys, Galderma, Mayne, and Regeneron and a consultant with honorarium for AbbVie, Eli Lilly, Janssen, Anaptsys, Galderma, Mayne, and Regeneron and a consultant with honorarium for AbbVie, Eli Lilly, Janssen, Anaptsys, Galderma, Mayne, and Regeneron and a consultant with honorarium for AbbVie, Eli Lilly, Janssen, Anaptsys, Galderma, Mayne, and Regeneron and a consultant with honorarium for AbbVie, Eli Lilly, Janssen, Anaptsys, Galderma, Mayne, and Regeneron and a consultant with honorarium for AbbVie, Eli Lilly, Janssen, Anaptsys, Galderma, Mayne, and Regeneron and a consultant with honorarium for AbbVie, Eli Lilly, Janssen, Anaptsys, Galderma, Mayne, and Regeneron and a consultant with honorarium for AbbVie, Eli Lilly, Janssen, Anaptsys, Galderma, Mayne, and Regeneron and a consultant with honorarium for AbbVie, Eli Lilly, Janssen, Anaptsys, Galderma, Mayne, and Regeneron and a consultant with honorarium for AbbVie, Eli Lilly, Janssen, Anaptsys, Galderma, Mayne, and Regeneron and a consultant with honorarium for AbbVie, Eli Lilly, Janssen, Anaptsys, Galderma, Mayne, and Regeneron and a consultant with honorarium for AbbVie, Eli Lilly, Janssen, Anaptsys, Galderma, Mayne, and Regeneron and a consultant with honorarium for AbbVie, Eli Lilly, Janssen, Anaptsys, Galderma, Mayne, and Regeneron and a consultant with honorarium for AbbVie, Eli Lilly, Janssen, Anaptsys, Galderma, Mayne, and Regeneron and a consultant with honorarium for AbbVie, Eli Lilly, Janssen, Anaptsys, Galderma, Mayne, and Regeneron and a consultant with honorarium for AbbVie, Eli Lilly, Janssen, Anaptsys, Galderma, Mayne, and Regeneron.

**REFERENCES**

1. Jones WN, Nix TE, Clark WH. Hemorrhagic Darier’s disease. *Arch Dermatol.* 1964;89(4):523-527. https://doi.org/10.1001/archderm.1964.01590280023003
2. Coulson IH, Misch KJ. Hemorrhagic Darier’s disease. *J R Soc Med.* 1989;82(6):365-366. https://doi.org/10.1177/014107688908200619
3. Gebauer K, Holgate C, Navaratnam A. Retinoid-induced hemorrhagic bullae in Darier’s disease. *Australas J Dermatol.* 1990;31(2):99-103. https://doi.org/10.1111/j.1440-0960.1990.tb00662.x
4. Foresman PL, Goldsmith LA, Ginn L, Beck AL. Hemorrhagic Darier’s disease. *Arch Dermatol.* 1993;129(4):511-512. https://doi.org/10.1001/archderm.1993.01680250127024
5. Regazzini R, Zambruno G, DeFilippi C, Rosso R, Donadini A. Isolated acral Darier’s disease with hemorrhagic lesions in a kindred in a kindred. *Br J Dermatol.* 1996;135(3):495-496. https://doi.org/10.1111/j.1365-2133.1996.tb01531.x
6. Jörg B, Erhard H, Rütten A. Eine hamorrhagische akrale verlaufsform der dyskeratosis follicularis Darier. *Hautarzt.* 2000;51(11):857-861. https://doi.org/10.1007/s001050051230
7. Ruiz-Perez VL, Carter SA, Heal Y, et al. ATP2A2 mutations in Darier’s disease: variant cutaneous phenotypes are associated with missense mutations, but neuropsychiatric features are independent of mutation class. *Hum Mol Genet.* 1999;8(9):1621-1630. https://doi.org/10.1093/hmg/8.9.1621
8. Pečina-Slaus M, Milavec-Puretić V, Kubat M, et al. Clinical case of acral hemorrhagic Darier’s disease is not caused by mutations in exon 15 of the ATP2A2 gene. *Coll Antropol.* 2003;27(1):125-133.
9. Hamada T, Yasumo S, Karashima T, et al. Recurrent p.N767S mutation in the ATP2A2 gene in a Japanese family with hemorrhagic Darier disease clinically mimicking epidermolysis bullosa simplex with mottled pigmentation. *Br J Dermatol.* 2007;157(3):605-608. https://doi.org/10.1111/j.1365-2133.2007.08086.x
10. Sánchez-Salas MP, Latasa de Araníbar FJ, Oncín Torres R, Gambó Grasa P. Bullous-hemorrhagic Darier disease. *Skimed.* 2011;9(1):65-66.
11. Zavattaro E, Celasco M, Delrosso G, et al. Acitretin-induced acral hemorrhagic lesions in Darier-White disease. *Cutis.* 2014;94(6):1-5.
12. Boes EE, Walling HW, Swick BL. Hemorrhagic macules on the palms and soles. *Clin Exp Dermatol.* 2016;41(4):449-450. https://doi.org/10.1111/ced.12778
13. Vender R, Vender R. Acral hemorrhagic Darier’s disease: a case report. *J Cutan Med Surg.* 2016;20(5):478-480. https://doi.org/10.1177/1203475416640993
14. Flores-Terry MA, García-Arpa M, Llamas-Velasco M, Mendoza-Chaparro C, Ramos-Rodríguez C. Acral hemorrhagic Darier disease. *Actas Dermosifiliogr.* 2017;108(7):e49-e52. https://doi.org/10.1016/j.adengl.2017.06.003
15. Nguyen Y, Satgunaseelan L, Lee S. A case of acitretin-induced hemorrhagic lesions in Darier disease. *Australas J Dermatol.* 2018;59(4):e301-e302. https://doi.org/10.1111/adj.12832
16. Trompezinski S, Pernet I, Schmitt D, Viac J. UV radiation and prostaglandin E2 up-regulate vascular endothelial growth factor (VEGF) in cultured human fibroblasts. *Inflamm Res.* 2001;50(8):422-427. https://doi.org/10.1007/PL00000265
17. Detmar M, Brown LF, Berse B, et al. Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin. *J Invest Dermatol.* 1997;108(3):263-268. https://doi.org/10.1111/1523-1747.ep12286453